2017 Press Releases

RSS Feeds RSS
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
DateTitle 
03/06/17Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular CarcinomaPrinter Friendly Version
03/01/17Exelixis Announces Webcasts of Investor Conference Presentations in MarchPrinter Friendly Version
02/28/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
02/27/17Exelixis Announces Clinical Trial Collaboration with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid TumorsPrinter Friendly Version
02/27/17Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell CarcinomaPrinter Friendly Version
02/27/17Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdatePrinter Friendly Version
02/17/17Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary TumorsPrinter Friendly Version
02/07/17Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15Printer Friendly Version
02/02/17Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017Printer Friendly Version
01/31/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
01/30/17Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in JapanPrinter Friendly Version
01/09/17Update on Dispute between Exelixis and Genentech, a Member of the Roche GroupPrinter Friendly Version
01/03/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version